Recent Quotes
View Full List
My Watchlist
Create Watchlist
Indicators
DJI
Nasdaq Composite
SPX
Gold
Crude+Oil
Local Stocks
WallStreetSelect 114
WallStreetSelect 114
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries
Repligen Corporation - Common Stock
(NQ:
RGEN
)
121.82
+0.69 (+0.57%)
Streaming Delayed Price
Updated: 12:17 PM EDT, Jun 3, 2026
Add to My Watchlist
Quote
Overview
Detailed Quote
Charting
Historical Prices
News
All News
News Headlines
Press Releases
Research
Quarterly Reports
Insider Filings
Other Filings
All News about Repligen Corporation - Common Stock
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Repligen (RGEN) To Report Earnings Tomorrow: Here Is What To Expect
February 22, 2026
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be reporting results this Tuesday before market hours. Here’s what to expect.
Via
StockStory
Topics
Artificial Intelligence
2 of Wall Street’s Favorite Stocks Worth Investigating and 1 We Avoid
February 19, 2026
The stocks in this article have caught Wall Street’s attention in a big way, with price targets implying returns above 20%. But investors should take these forecasts with a grain of salt because...
Via
StockStory
3 Volatile Stocks Walking a Fine Line
February 02, 2026
Volatility cuts both ways - while it creates opportunities, it also increases risk, making sharp declines just as likely as big gains. This unpredictability can shake out even the most experienced...
Via
StockStory
2 Cash-Producing Stocks to Target This Week and 1 We Ignore
January 28, 2026
While strong cash flow is a key indicator of stability, it doesn’t always translate to superior returns. Some cash-heavy businesses struggle with inefficient spending, slowing demand, or weak...
Via
StockStory
Earnings Scheduled For October 28, 2025
↗
October 28, 2025
Via
Benzinga
3 Reasons to Sell RGEN and 1 Stock to Buy Instead
January 26, 2026
Repligen has had an impressive run over the past six months as its shares have beaten the S&P 500 by 28.3%. The stock now trades at $163.29, marking a 36.5% gain. This was partly due to its solid...
Via
StockStory
Topics
Stocks
3 High-Flying Stocks That Fall Short
January 18, 2026
Expensive stocks often command premium valuations because the market thinks their business models are exceptional. However, the downside is that high expectations are already baked into their prices,...
Via
StockStory
Why Repligen (RGEN) Shares Are Sliding Today
January 14, 2026
Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) fell 3.9% in the afternoon session after the company presented at the JPMorgan Healthcare Conference and shared its sales...
Via
StockStory
Topics
Artificial Intelligence
1 Cash-Heavy Stock to Target This Week and 2 Facing Challenges
January 05, 2026
A cash-heavy balance sheet is often a sign of strength, but not always. Some companies avoid debt because they have weak business models, limited expansion opportunities, or inconsistent cash flow.
Via
StockStory
1 Volatile Stock to Target This Week and 2 We Turn Down
December 07, 2025
Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor...
Via
StockStory
Why Repligen (RGEN) Stock Is Trading Up Today
November 21, 2025
Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 5.7% in the afternoon session after comments from a key Federal Reserve official bolstered hopes for an interest rate...
Via
StockStory
Topics
Artificial Intelligence
Economy
Stocks
Lantheus, Enovis, Evolent Health, Repligen, and Corcept Shares Are Soaring, What You Need To Know
November 11, 2025
A number of stocks jumped in the afternoon session after the market experienced a sharp sector rotation, as investors fled growth-oriented technology stocks and piled into value-oriented names amid...
Via
StockStory
Topics
Artificial Intelligence
Stocks
3 Cash-Producing Stocks We Approach with Caution
November 10, 2025
A company that generates cash isn’t automatically a winner. Some businesses stockpile cash but fail to reinvest wisely, limiting their ability to expand.
Via
StockStory
Drug Development Inputs & Services Stocks Q3 Recap: Benchmarking Repligen (NASDAQ:RGEN)
November 06, 2025
Earnings results often indicate what direction a company will take in the months ahead. With Q3 behind us, let’s have a look at Repligen (NASDAQ:RGEN) and its peers.
Via
StockStory
5 Revealing Analyst Questions From Repligen’s Q3 Earnings Call
November 04, 2025
Repligen’s third quarter saw revenue and non-GAAP profit exceed Wall Street expectations, yet the market responded negatively. Management attributed the quarter’s strong top-line performance to...
Via
StockStory
Topics
Earnings
3 Hyped Up Stocks with Open Questions
October 30, 2025
The stocks in this article are all trading near their 52-week highs. This strength often reflects positive developments such as new product launches, favorable industry trends, or improved financial...
Via
StockStory
RGEN Q3 Deep Dive: Robust Product Demand Offset by Margin Pressures and Guidance Reset
October 29, 2025
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) announced better-than-expected revenue in Q3 CY2025, with sales up 21.9% year on year to $188.8 million. The company’s full-year...
Via
StockStory
Why Repligen (RGEN) Shares Are Trading Lower Today
October 28, 2025
Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) fell 4.2% in the afternoon session after the company reported third-quarter results that beat revenue and profit...
Via
StockStory
Topics
Economy
Government
World Trade
Repligen Corp (NASDAQ:RGEN) Posts Strong Q3 2025 Results, Beating Revenue and EPS Estimates
↗
October 28, 2025
Repligen's Q3 2025 results beat earnings and revenue estimates, driving a positive market reaction and raising full-year guidance.
Via
Chartmill
Repligen’s (NASDAQ:RGEN) Q3 Sales Beat Estimates
October 28, 2025
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) announced better-than-expected revenue in Q3 CY2025, with sales up 21.9% year on year to $188.8 million. The company’s full-year...
Via
StockStory
Topics
Earnings
Repligen Earnings: What To Look For From RGEN
October 26, 2025
Biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) will be reporting results this Tuesday before market hours. Here’s what investors should know.
Via
StockStory
Topics
Artificial Intelligence
3 Inflated Stocks with Questionable Fundamentals
October 21, 2025
The stocks featured in this article are seeing some big returns. Over the past month, they’ve outpaced the market due to some combination of positive news, upbeat results, or supportive macro...
Via
StockStory
Myriad Genetics, Omnicell, Globus Medical, Repligen, and Teleflex Stocks Trade Down, What You Need To Know
October 10, 2025
A number of stocks fell in the afternoon session after worries over worsening trade relations with China were triggered by critical comments from President Donald Trump.
Via
StockStory
Topics
Economy
Government
World Trade
Federal Reserve Signals Further Rate Cuts Amidst Worsening Labor Market and Divided Opinions
October 14, 2025
Washington D.C. – The Federal Reserve has sent clear signals of a continued dovish pivot, with Chair Jerome Powell indicating the likelihood of two additional quarter-point interest rate cuts before...
Via
MarketMinute
Topics
Artificial Intelligence
Bonds
Credit Cards
Thermo Fisher Scientific Soars on Strategic Wins, Market Optimism
October 01, 2025
Thermo Fisher Scientific Inc. (NYSE: TMO) experienced a robust surge in its stock value today, October 1, 2025, climbing an impressive 9.79% as market optimism swelled around a series of recent...
Via
MarketMinute
Topics
Artificial Intelligence
Economy
Government
What 8 Analyst Ratings Have To Say About Repligen
↗
October 01, 2025
Via
Benzinga
Why Is Repligen (RGEN) Stock Soaring Today
October 01, 2025
Shares of biopharma manufacturing company Repligen Corporation (NASDAQ:RGEN) jumped 6.6% in the afternoon session after HSBC initiated coverage on the stock with a 'Buy' rating and a $150 price...
Via
StockStory
Topics
Government
Repligen, BrightSpring Health Services, Danaher, Thermo Fisher, and Amgen Shares Skyrocket, What You Need To Know
September 30, 2025
A number of stocks jumped in the afternoon session after reports revealed a potential drug-pricing agreement between the White House and the pharmaceutical industry.
Via
StockStory
Topics
Government
1 Volatile Stock to Target This Week and 2 Facing Challenges
September 25, 2025
Market swings can be tough to stomach, and volatile stocks often experience exaggerated moves in both directions. While many thrive during risk-on environments, many also struggle to maintain investor...
Via
StockStory
3 Reasons to Sell RGEN and 1 Stock to Buy Instead
September 24, 2025
Over the past six months, Repligen’s shares (currently trading at $123.26) have posted a disappointing 15.1% loss, well below the S&P 500’s 15.5% gain. This might have investors contemplating their...
Via
StockStory
Topics
Stocks
< Previous
1
2
3
4
5
6
7
8
9
10
Next >
Stock Quote API & Stock News API supplied by
www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the
Privacy Policy
and
Terms Of Service
.
© 2025 FinancialContent. All rights reserved.
